Search

everythinglearnresearchcommunity

for

Search:↓

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The user has been using finasteride for 2 years, nizoral for 1.5 years, topical minoxidil for 1 year, and microneedling for 3 months to treat hair loss but hasn't seen improvement or regrowth, even experiencing shedding with new treatments. They are concerned about continued thinning despite the treatments.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

A 22-year-old male shared his 4-month progress using Minoxidil, finasteride, and weekly micro-needling for hair loss, reporting no negative side effects and feeling content with his results. Replies were supportive and encouraging.

The user received hormone test results showing normal estradiol and testosterone levels, low SHBG, and normal free androgen index. They are considering starting finasteride but are concerned due to being slightly overweight.

The post and conversation are about a user's 10-month update on natural hair loss treatment, with mixed feedback on its effectiveness. Some suggest using finasteride and minoxidil for better results.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

The conversation discusses using Morr F Aqua, an alcohol-free version of Minoxidil, for hair loss, particularly for someone with dandruff issues. The user is considering if this product is suitable for their condition.

The user experienced chest pain and increased heart rate after microneedling while using topical minoxidil for hair loss. They are unsure if minoxidil is effective without microneedling.

Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.

The conversation discusses hair regrowth using finasteride, minoxidil, ketoconazole shampoo (Nizoral), and microneedling as treatments. Users are sharing their experiences and results with these specific hair loss treatments.

The user reports some hair regrowth after two months of using 1.5mm microneedling with Minoxidil and Nizoral shampoo. They note reduced pain and skin flaking, attributing changes to skin thickening and collagen induction.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conclusion of the conversation is that the user should consider using treatments such as finasteride, minoxidil, and RU58841 to potentially reverse their hair loss. Other suggestions include using hair loss concealers and maintaining a healthy diet.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

The conversation discusses the correct method of microneedling for hair loss, questioning whether it should be done on areas with long hair without risking hair damage, and if it's necessary for improving blood flow to existing hair. No specific treatments were mentioned.

N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.

Treating androgenic alopecia with minoxidil, finasteride, and antiandrogens, alongside exercise, cryotherapy, and natural substances to stimulate cold receptors for better hair growth. The method focuses on enhancing treatment effectiveness by considering environmental and behavioral factors and the role of cold receptors and muscle stress.

The conversation humorously discusses hair loss treatments like finasteride, minoxidil, and dutasteride, referencing a "Smiling Friends" episode. It includes jokes about hair loss, AI-generated images, and the show's satire on societal perceptions of baldness.

Treatments for androgenic hair loss, including the use of finasteride, minoxidil, nizroal and microneedling/dermarolling. Side effects are discussed and it is noted that while there are tradeoffs to taking medications, they are generally safe and effective.

Microneedling can cause infections if not done carefully; users suggest using alcohol swabs and reducing needle depth to avoid issues. Proper sanitation and gentle pressure are key to preventing bleeding and infection.

The conversation is about coping with hair loss and includes advice on improving overall appearance and confidence. Specific hair loss treatments mentioned are not discussed.

The user has been using finasteride, dutasteride, and RU58841 for hair loss without success and feels extremely uncomfortable with their appearance, including being bald and short. They express deep unhappiness and social isolation. Suggestions from others include adopting stoicism, focusing on personal development, considering a hair system, improving fashion, working out, and seeking therapy for mental health.

The conversation discusses the steps for microneedling, specifically differentiating between medical needling (0.5-1.5mm) and cosmetic needling (0.3mm). It emphasizes the importance of cleaning and disinfecting before microneedling, regardless of needle length.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A user added 1% NMN to their 5% minoxidil mix for hair loss, which also includes melatonin, ginkgo, nettle root, and plans to add caffeine. They are asking if anyone has tried topical NMN for hair growth.